Patents by Inventor Nasreen Jacobson

Nasreen Jacobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

COMPOSITIONS OF DECIDUA TISSUE AND USES THEREOF

Publication number: 20240408267

Abstract: Disclosed are compositions and methods for treating wounds and damaged tissue using decidua tissue.

Type: Application

Filed: September 29, 2022

Publication date: December 12, 2024

Applicant: OSIRIS THERAPEUTICS, INC.

Inventors: Nasreen JACOBSON, Jin-Qiang KUANG, Min Sung PARK, Aleksa JOVANOVIC
Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteins

Publication number: 20120101160

Abstract: The present invention provides methods for treating glaucoma by administering compounds capable of stabilizing misprocessed or misfolded proteins that are responsible for the condition.

Type: Application

Filed: December 14, 2005

Publication date: April 26, 2012

Inventors: Allan Shepard, Nasreen Jacobson, Abbot F. Clark
AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES

Publication number: 20110092523

Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Type: Application

Filed: December 16, 2010

Publication date: April 21, 2011

Applicant: ALCON RESEARCH, LTD.

Inventors: Debra L. Fleenor, Allan Shepard, Nasreen Jacobson, Iok-Hou Pang, Abbot F. Clark
AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES

Publication number: 20080176964

Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Type: Application

Filed: February 1, 2008

Publication date: July 24, 2008

Applicant: ALCON RESEARCH, LTD.

Inventors: Debra L. Fleenor, Allan Shepard, Nasreen Jacobson, Iok-Hou Pang, Abbot F. Clark
Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Patent number: 7351407

Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Type: Grant

Filed: April 18, 2003

Date of Patent: April 1, 2008

Assignee: Alcon, Inc.

Inventors: Debra L. Fleenor, Allan Shepard, Nasreen Jacobson, Iok-Hou Pang, Abbot F. Clark
Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Publication number: 20060275797

Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one agent that inhibits binding and/or signaling of connective tissue growth factor (CTGF) via the TrkA/p75NTR receptor complex.

Type: Application

Filed: March 20, 2006

Publication date: December 7, 2006

Inventors: Allan Shepard, Nasreen Jacobson, Abbot Clark
Use of cathepsin k inhibitors for the treatment of glaucoma

Publication number: 20060020001

Abstract: Compositions containing inhibitors of cathepsin K (CTSK) expression and/or activity are provided. Methods for the treatment of glaucoma using the compositions of the invention are further provided.

Type: Application

Filed: December 19, 2003

Publication date: January 26, 2006

Inventors: Allan Shepard, Abbot Clark, Nasreen Jacobson
Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Publication number: 20050234075

Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Type: Application

Filed: April 18, 2003

Publication date: October 20, 2005

Inventors: Debra Fleenor, Allan Shepard, Nasreen Jacobson, Iok-Hou Pang, Abbot Clark
Short form c-Maf transcription factor antagonists for treatment of glaucoma

Publication number: 20050159432

Abstract: The short form version of c-Maf transcription factor is up-regulated in steroid-treated and transforming growth factor beta2-treated trabecular meshwork cells, and is present at elevated levels in glaucomatous versus normal trabecular meshwork cells and in glaucomatous versus normal optic nerve head tissue. Expression of short form c-Maf transcription factor under these conditions indicates a causal or effector role for the factor in primary open-angle and steroid-induced glaucoma pathogenesis. Antagonism of short form c-Maf transcription factor expression and/or activity in the trabecular meshwork or other ocular tissue is provided for inhibiting or alleviating glaucoma pathogenesis. Antagonists include cyclin-dependent kinase 2 inhibitors.

Type: Application

Filed: December 21, 2004

Publication date: July 21, 2005

Applicant: Alcon, Inc.

Inventors: Allan Shepard, Nasreen Jacobson, Abbot Clark